期刊
EUROPEAN UROLOGY
卷 66, 期 3, 页码 459-465出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.eururo.2013.11.044
关键词
Castration-resistant prostate cancer; Cabazitaxel; Abiraterone; Enzalutamide; Treatment sequencing
资金
- Amgen
- Astellas
- Takeda
- Succinct Healthcare
- Sanofi-Aventis
- Janssen-Cilag
- Bayer
- BNIT
- Ortho Biotech Oncology Research and Development
- AstraZeneca
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- Dendreon
- Enzon
- Exelixis
- Genentech
- GlaxoSmithKline
- Medication
- Merck
- Novartis
- Pfizer
- Roche
- SanofiAventis
- Supergen
- Cancer Research UK programme grant
- Cancer Research UK
- Department of Health [C51/A7401]
- Swiss Cancer League [BIL KLS-02592-02-2010]
- Cancer Research UK Clinician Scientist Fellowship
- Prostate Cancer UK
- Prostate Cancer Foundation
- Cancer Research UK [13239] Funding Source: researchfish
- National Institute for Health Research [CL-2008-22-001] Funding Source: researchfish
Background: Cabazitaxel, abiraterone, and enzalutamide are survival-prolonging treatments in men with castration-resistant prostate cancer (CRPC) progressing following docetaxel chemotherapy. The sequential activity of these agents has not been studied and treatment sequencing remains a key dilemma for clinicians. Objective: To describe the antitumour activity of cabazitaxel after docetaxel and next-generation endocrine agents. Design, setting, and participants: We report on a cohort of 59 men with progressing CRPC treated with cabazitaxel, 37 of whom had received prior abiraterone and 9 of whom had received prior enzalutamide. Outcome measurements and statistical analysis: Changes in prostate-specific antigen (PSA) level were used to determine activity on abiraterone, enzalutamide, and cabazitaxel treatment. Radiologic tumour regressions according to Response Evaluation Criteria in Solid Tumors (RECIST) and symptomatic benefit were evaluated for cabazitaxel therapy. Results and limitations: The post-endocrine-therapy patients received abiraterone (n = 32), sequential abiraterone and enzalutamide (n = 5) or enzalutamide (n = 4). These patients received a median of 7mo of abiraterone and 11 mo of enzalutamide. A median of six cabazitaxel cycles (range: 1-10 cycles) were delivered, with >= 50% PSA declines in 16 of 41 (39%) patients, soft tissue radiologic responses in 3 of 22 (14%) evaluable patients, and symptomatic benefit in 9 of 37 evaluable patients (24%). Median overall survival and progression-free survival were 15.8 and 4.6 mo, respectively. Antitumor activity on cabazitaxel was less favourable in the abiraterone-and enzalutamide-naive cohort (n = 18), likely reflecting biologic differences in this cohort. These data were obtained from a retrospective analysis. Conclusions: This is the first report of cabazitaxel activity in CRPC progressing after treatment with docetaxel and abiraterone or enzalutamide. We demonstrate significant cabazitaxel activity in this setting. Patient summary: We looked at the antitumour activity of the chemotherapy drug cabazitaxel in men previously treated with docetaxel chemotherapy and the hormonal drugs abiraterone and enzalutamide. Cabazitaxel appeared active when given after abiraterone and enzalutamide. We can reassure men that cabazitaxel can be used after these novel endocrine treatments. (C) 2013 European Association of Urology. Published by Elsevier B. V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据